AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.11+0.04 (+0.01%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB61.10+0.13 (+0.21%) ▲|V422.97+1.34 (+0.32%) ▲|VZ45.98-0.10 (-0.22%) ▼|WFC85.76+0.26 (+0.30%) ▲|WMT125.35-0.32 (-0.25%) ▼|XOM161.78-2.98 (-1.81%) ▼|AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.11+0.04 (+0.01%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB61.10+0.13 (+0.21%) ▲|V422.97+1.34 (+0.32%) ▲|VZ45.98-0.10 (-0.22%) ▼|WFC85.76+0.26 (+0.30%) ▲|WMT125.35-0.32 (-0.25%) ▼|XOM161.78-2.98 (-1.81%) ▼|
9.9 C
New York
Tuesday, November 10, 2026

Tag: health

Samsung Biologics launches drug screening services, Samsung Organoids

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire/ --...

Readout – Prime Minister Carney meets with Prime Minister of the United Kingdom Sir Keir Starmer

OTTAWA, ON, June 15, 2025 /CNW/ - Today, the Prime Minister, Mark Carney, met with the Prime Minister of the United Kingdom (UK), Sir...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Gold Coast Health Plan Denounces Sharing of Medicaid Enrollment Data with Department of Homeland Security

CAMARILLO, Calif., June 14, 2025 /PRNewswire/ -- Gold Coast Health Plan (GCHP), the local Medi-Cal plan for Ventura County, is deeply concerned about the...

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

ELV SHAREHOLDERS: Elevance Health, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 11 Deadline (NYSE:ELV)

Elevance Health, Inc. investors that lost money are notified to contact BFA Law before July 11, 2025 securities fraud class action deadline.

HSA/FSA Eligible Adjustable Dumbbells & Home Gym Equipment

Save Up to 40% on Core's Space-Saving Home Gym Equipment with HSA/FSA via Truemed(Individual tax rates vary). YOUNGSTOWN, Ohio, June 14, 2025 /PRNewswire/ -- Core...

OGN SHAREHOLDERS: Organon & Co. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 22 Deadline (NYSE:OGN)

Organon & Co. investors that lost money are notified to contact BFA Law before July 22, 2025 securities fraud class action deadline.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHealth